Antibody-dependent cellular cytotoxicity of natural killer cells

Trastuzumab promotes natural killer cell activation through antibody-dependent cellular cytotoxicity (ADCC). Understanding ADCC can help researchers develop immunotherapies with better targeting and efficacy. In this application note, Axion Biosystems examines and quantifies ADCC-specific killing using the monoclonal antibody trastuzumab and peripheral blood natural killer cells on the Maestro z. The ADCC response between donors and across multiple effector to target cell ratios is compared.